BioAtla, Inc. BCAB 深 滬
已收盤 04-02 16:00:00 美东时间
0.1304
-0.004
-3.12%
華盛通- 最 高0.1388
- 今 開0.137
- 成交量 106.72万股
- 最 低 0.1275
- 昨 收 0.1346
- 總市值 1080.32万
- 52周最高 1.43
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 0.12
- 委 比 99.15%
- 總股本 8284.63万
- 歷史最高 76.63
- 量 比 0.81
- 振 幅 8.40%
- 歷史最低 0.12
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
BioAtla Begins Strategic Review Following 2025 Results
BioAtla ( ($BCAB) ) has shared an update. On March 31, 2026, BioAtla reported f...
04-01 07:46
BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.30) by 47.19 percent. This is a 46.67 percent increase over losses of $(0.30) per share from the same
04-01 05:03
BioAtla shares are trading lower after the company announced a 50-for-1 share consolidation.
BioAtla shares are trading lower after the company announced a 50-for-1 share c...
04-01 04:20
BioAtla to implement 50-for-1 share consolidation
BioAtla (BCAB) on Tuesday said it will carry out a 50-for-1 share consolidation of its common stock, effective April 6, 2026, as it seeks to raise its share price to meet the $1.00 minimum bid require...
04-01 04:12
BioAtla Announces 50-For-1 Share Consolidation, Effective April 6
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that
04-01 04:09
BioAtla Announces Share Consolidation
BioAtla, Inc. announces a 50-for-1 share consolidation of its common stock, effective April 6, 2026, to increase the stock's trading price and regain compliance with Nasdaq's $1.00 minimum bid price requirement. Each shareholder will receive one share of common stock for every fifty shares held, with fractional shares converted to cash based on the stock's closing price on the effective date. The consolidation will not change the par value or aut...
03-31 20:06
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BioAtla Inc. announced financial results for 2025 and outlined strategic initiatives, including exploring asset monetization and restructuring to reduce costs and extend runway. The company reported lower R&D and G&A expenses, resulting in a narrowed net loss. Despite facing financial challenges, including limited cash reserves, BioAtla remains focused on advancing its clinical pipeline, notably BA3182 in adenocarcinoma and Ozuriftamab Vedotin fo...
03-31 20:05
BioAtla Shareholders Approve Merger and Share Consolidation
BioAtla ( ($BCAB) ) just unveiled an announcement. On March 23, 2026, BioAtla r...
03-24 04:41
BioAtla Board Initiates Formal Process To Explore And Evaluate Strategic Options To Monetize Assets
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the
03-02 20:38
